Background There is comparatively little information in the public domain on the diversity in
prevalence and triggers/factors associated with allergic rhinitis ( AR ) or allergic …

Chronic inflammatory airway diseases, including asthma, chronic rhinosinusitis, eosinophilic
COPD and allergic rhinitis are a global health concern. Despite the coexistence of these …

… Crisci c Sergio Del Giacco d Anthony J. Frew a GH Liu e Jorge Maspero f Hee-Bom
Moon g Takemasa Nakagawa h Paul C. Potter i Lanny J. Rosenwasser …

Background Dupilumab is a fully human anti–interleukin-4 receptor α monoclonal antibody
that blocks both interleukin-4 and interleukin-13 signaling. We assessed its efficacy and …

Background Elevated numbers of blood eosinophils are a risk factor for asthma exacerbations.
Reslizumab is a humanised anti-interleukin 5 monoclonal antibody that disrupts …

Background Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) generally
have a high symptom burden and poor health-related quality of life, often requiring recurring …

Background Chronic rhinosinusitis with nasal polyps affects approximately 2–4% of the
general population, and long-term use of systemic corticosteroids is associated with adverse …

Background Dupilumab is a fully human anti–interleukin-4 receptor α monoclonal antibody
that blocks both interleukin-4 and interleukin-13 signaling. Its effectiveness in reducing oral …

Background Dupilumab, a fully human anti-interleukin-4 receptor α monoclonal antibody,
inhibits interleukin-4 and interleukin-13 signalling, key drivers of type-2-mediated inflammation…

Background Monoclonal antibodies targeting IgE, interleukin-4 and -13, and interleukin-5 are
effective in treating severe type 2 asthma, but new targets are needed. Itepekimab is a new …